Supplement Firms Have ‘Continuous Monitoring’ Burden To Show Product Safety
This article was originally published in The Pink Sheet Daily
Former FDA supplement programs head Bill Frankos says the industry bears the burden for monitoring product safety in the marketplace because FDA does not have the same vested interest it has for drugs and medical devices stemming from pre-market approval of the products.
You may also be interested in...
The successor to Vasilios "Bill" Frankos, FDA's director of Dietary Supplement Programs, will face a full plate of imminent and ongoing regulatory issues
FDA is extending the deadline for serious adverse event labeling requirements for OTC drugs and dietary supplements until January 2010 because it has yet to finalize its guidance to comply with those regulations
The dietary supplement good manufacturing practices final rule provides "a very flexible framework for required testing," said Vasilios H. Frankos, director of the dietary supplement programs division for FDA's Center for Food Safety and Applied Nutrition